Shkreli says he isn’t responsible for Daraprim ‘monopoly’
Jailed ‘pharma bro’ Martin Shkreli has told a US federal court he is not responsible for antitrust violations alleged by the US Federal Trade Commission.
AstraZeneca and Daiichi Sankyo to jointly develop another new cancer treatment
Biopharmaceutical company AstraZeneca has struck a deal with Japanese pharmaceutical company Daiichi Sankyo to jointly develop and market a new medicine to treat lung, breast and other cancers.
US authorities seize counterfeit Viagra and Zantac at airport
Counterfeit pills used to treat erectile dysfunction, heartburn and stomach ulcers have been discovered at Los Angeles International Airport (LAX), alongside fake luxury goods.
Roche stakes $2bn on UCB Alzheimer’s disease treatment
Swiss company Roche has partnered with Belgium-based biopharmaceutical company UCB to develop an antibody treatment for people living with Alzheimer’s disease.
University can claim sovereign immunity in cancer treatment suit, rules Federal Circuit
The University of Texas is protected from being forced to become an involuntary plaintiff in an infringement suit because of sovereign immunity, the US Court of Appeals for the Federal Circuit ruled on Friday, July 24.
Ninth Circuit affirms California’s pay-for-delay ban
A US federal appeals court has refused to block California’s ban on pay-for-delay deals in the generic drugs industry.
Moderna loses bid to invalidate Arbutus patent
Biotech company Moderna has failed to have a US patent owned by its competitor Arbutus Biopharma revoked, following a decision handed down by the Patent Trial and Appeal Board (PTAB).
Sun Pharma to pay $205m over generics price-fixing
A subsidiary of India’s Sun Pharma has agreed to pay more than $200 million to settle charges related to a generics price-fixing investigation.
US to pay Pfizer nearly $2bn for COVID-19 vaccine supply
Pfizer and its German partner BioNTech will receive nearly $2 billion from the US in exchange for the supply of 100 million doses of an experimental coronavirus vaccine.
USITC to investigate Novartis patent complaint against Regeneron
The US International Trade Commission (USITC) will investigate Regeneron Pharmaceuticals for the alleged infringement of a patent owned by its rival Novartis, it announced in a notice posted yesterday, July 21.
